Clinical Trials Logo

Clinical Trial Summary

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04657289
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: WR42221 https://forpatients.roche.com
Phone 888-662-6728 (U.S. and Canada)
Email global-roche-genentech-trials@gene.com
Status Recruiting
Phase Phase 3
Start date July 14, 2021
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04543331 - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Recruiting NCT05904691 - Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration Phase 1
Completed NCT05282004 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit Phase 3
Active, not recruiting NCT04764656 - Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Completed NCT05269966 - Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Phase 4
Completed NCT05161806 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe Phase 3
Recruiting NCT06116890 - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration Phase 2
Recruiting NCT06075147 - The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
Terminated NCT04746963 - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Recruiting NCT05769153 - Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) Phase 1/Phase 2
Enrolling by invitation NCT05210803 - Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Recruiting NCT04514653 - RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Phase 2
Not yet recruiting NCT06398080 - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3